(SeaPRwire) –   By: Logan Pierce

On June 4, 2026, Lupin Limited made a significant announcement. The U.S. FDA had approved its ranibizumab, Ranluspec™, as an interchangeable biosimilar referencing Lucentis®. This is a major milestone for Lupin, adding depth to its biosimilars portfolio.

Ranluspec is the only interchangeable biosimilar ranibizumab approved in the U.S. in both vials and pre-filled syringes, in two strengths. It treats various vision problems. Lupin’s leaders highlighted how this reflects their progress in complex biologics and commitment to patient access.

Lupin, a global pharma leader based in Mumbai, has products in over 100 markets. With 15 manufacturing sites and 7 research centers, it’s well-positioned. This approval is a win for patients seeking affordable vision therapies.
Author bio: Logan Pierce, independent business writer covering pharma and biotech on Medium.